Bid Banana
PricingBid helpAPILog inStart free trial
Log inStart free trial

Before you respond

  • Federal grantsHow to Find Grants for Nonprofits
  • Healthcare RFPsHealthcare and Medical Services Bids and Bidding Guide
  • How to apply for a grantGrant Applications vs. RFPs: Writing Differences Explained
More healthcare and medical services bids →Must-win bid? Bring in The Bid Lab →
Bid Banana
SearchPricingBid helpBrowse bidsAPISupportFAQPrivacy PolicyTerms of UseAI Use Policy

This website and its content is copyright of The Bid Lab © 2026. The Bid Lab is a trademark of Bid Lab, LLC. All rights reserved.

  1. Bid Banana
  2. ›Bids
  3. ›Federal
  4. ›Catalyze: Enabling Technologies and Transformative…

U.S. National Institutes of Health·United States of America

Catalyze: Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed)

Closes 12/23/2027$350kGrants Notice
Get bids like this by emailBid source

Description

The goal of the NHLBI Catalyze Program is to provide support and services to facilitate the transition of basic science discoveries into viable diagnostic and therapeutic candidates. This specific initiative will support the validation of transformative, multi-use platforms or technologies that can enable significant acceleration and/or transformation in areas such as early detection and screening, model development, clinical diagnosis, treatment, control, behavior, prevention, or epidemiology related to heart, lung, blood, and sleep (HLBS) disorders. • The program aims to develop translational researchers fluent in product development and entrepreneurship. • Proposed platforms and technologies must have the potential to improve the outlook for HLBS-related diseases and disorders. • Applications must offer the potential to significantly accelerate and/or transform the areas of early detection and screening, model development, clinical diagnosis, treatment, control, behavior, prevention, or epidemiology. • The award ceiling for this opportunity is $350,000.

Attached files

Contact

[email protected]

Key dates

Opened
1/24/2022
Closes
12/23/2027

Last updated

Details

Type
Grants Notice
Industry
Healthcare and Medical Services
NAICS
541710
Solicitation №
RFA-HL-26-016

Budget estimate

$350,000

The Award Ceiling is explicitly stated on the source site.

Similar opportunities

Matched by Bid Banana AI™

Bid Banana · 1.6M+ bids and awards 🍌

You found this one. Bid Banana has 1.6M+ bids and awards.

You found this bid by looking. Bid Banana searches open government bids across all 50 states, updated daily, so you stop hunting: save a search once and we email you your new matches, daily or weekly.

1.6M+
bids & awards
All 50
states
4,000+
agencies
Start your 7-day free trial

Plans from $49.99/month. Cancel anytime, no setup fees.

Built by The Bid Lab, answering RFPs since 2017.

U.S. National Institutes of Health·United States of America

Top match · 89%

Catalyze: Product Definition for Small Molecules, Biologics, and Combination Products - Preliminary Product/Lead Series Identification and Combination Product Prototype (R33 - Clinical Trial Not Allowed)

Closes 12/23/2027Opened 11/22/2024

U.S. National Institutes of Health·United States of America

88% match

Catalyze: Product Definition for Small Molecules, Biologics and Combination Products - Target Identification and Validation, and Preliminary Product/Lead Series Identification (R61/R33 Clinical Trials Not Allowed)

Closes 12/23/2027Opened 11/22/2024

U.S. National Institutes of Health·United States of America

86% match

Catalyze: Product Definition Medical Device Prototype Optimization (R33 - Clinical Trial Not Allowed)

Closes 12/23/2027Opened 11/22/2024

U.S. National Institutes of Health·United States of America

85% match

Catalyze Product Definition Medical Device prototype design/testing and disease target identification and assay development (R61/R33 - Clinical Trial Not Allowed)

Closes 12/23/2027Opened 11/22/2024

U.S. National Institutes of Health·United States of America

84% match

NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R61/R33 Clinical Trial Required)

Closes 2/3/2027Opened 4/2/2024

U.S. National Institutes of Health·United States of America

83% match

NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R33 CT Required)

Closes 2/3/2027Opened 4/1/2024

U.S. National Institutes of Health·United States of America

81% match

NHLBI TOPMed: Omics Phenotypes of Heart, Lung, and Blood Disorders (X01 - Clinical Trial Not Allowed)

Closes 5/8/2028Opened 7/8/2025

U.S. National Institutes of Health·United States of America

80% match

Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Neurotherapeutic Agent Identification (R61/R33 Clinical Trial Not Allowed)

Closes 10/20/2027Opened 10/22/2024

U.S. National Institutes of Health·United States of America

79% match

Development of Models, New Approach Methodologies, and Biological Materials for Studying Human Health and Diseases (R21 Clinical Trial Not Allowed)

Closes 2/15/2028Opened 9/16/2026

U.S. National Institutes of Health·United States of America

78% match

Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)

Closes 6/3/2027Opened 7/14/2026

U.S. National Institutes of Health·United States of America

78% match

Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)

Closes 10/20/2027Opened 10/22/2024

U.S. National Institutes of Health·United States of America

78% match

Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems to Facilitate Neurotherapeutic Discovery (R61/R33 Clinical Trial Not Allowed)

Closes 10/20/2027Opened 10/22/2024

U.S. National Institutes of Health·United States of America

78% match

Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)

Closes 11/10/2026Opened 9/8/2025

U.S. National Institutes of Health·United States of America

77% match

NHLBI Clinical Trial Pilot Studies (R34 Clinical Trial Optional)

Closes 3/16/2027Opened 11/3/2023

U.S. National Institutes of Health·United States of America

77% match

Limited Competition: High Impact Specialized Innovation Programs in Clinical and Translational Science

Closes 1/24/2027Opened 7/20/2026

U.S. National Institutes of Health·United States of America

77% match

Bioengineering Partnerships with Industry (U01 Clinical Trial Optional)

Closes 9/7/2027Opened 3/8/2022

U.S. National Institutes of Health·United States of America

77% match

NHLBI Outstanding Investigator Award (OIA) (R35 Clinical Trial Optional)

Closes 4/28/2027Opened 4/26/2024

U.S. National Institutes of Health·United States of America

77% match

Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)

Closes 6/3/2027Opened 7/14/2026

U.S. National Institutes of Health·United States of America

76% match

Limited Competition: Stimulating Access to Research in Residency Transition Scholar (StARRTS) (K38 Clinical Trial Not Allowed)

Closes 10/13/2028Opened 7/1/2025

U.S. National Institutes of Health·United States of America

76% match

Limited Competition: Small Grant Program for NHLBI K01/K08/K23/K25 Recipients (R03 Clinical Trial Optional)

Closes 11/7/2028Opened 7/18/2025

U.S. National Institutes of Health·United States of America

76% match

Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Not Allowed)

Closes 1/7/2028Opened 3/25/2021

U.S. National Institutes of Health·United States of America

76% match

NEI Translational Research Program for Therapeutics (R61/R33 Clinical Trial Not Allowed)

Closes 11/16/2029Opened 9/9/2025

U.S. National Institutes of Health·United States of America

76% match

HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allowed)

Closes 1/15/2027Opened 9/18/2024

U.S. National Institutes of Health·United States of America

76% match

Technology Development Program

Closes 2/4/2028Opened 9/16/2026

U.S. National Institutes of Health·United States of America

76% match

Limited Competition: Clinical and Translational Science Award (CTSA) Program: Collaborative and Innovative Acceleration Award (UG3/UH3 Clinical Trial Optional)

Closes 10/19/2027Opened 12/11/2024